Literature DB >> 30531235

Idiopathic Thrombocytopenic Purpura Induced by Synthetic Cannabinoid.

Giselle Castaneira1, Kelley Rojas, Yehuda Galili, Zachary Field, Ariel Perez-Perez, Mario Madruga, Steve J Carlan.   

Abstract

: Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder defined as low platelet count with normal bone marrow in the absence of other causes of thrombocytopenia. It is caused by autoantibodies binding to several platelet surface antigens which lead to premature destruction of the platelet by the reticuloendothelial system. ITP can be primary or secondary, and it is known to be associated with various infections and drugs. K2/Spice, or synthetic marijuana, acts on cannabinoid receptors CB1 (cannabinoid type-1) and CB2 (cannabinoid type-2) with increased binding capacity compared to marijuana. A white male was brought to the emergency department with signs of acute drug toxicity. His urine drug test was negative but he admitted to a year long history of synthetic marijuana use. His platelet count was 12,000/mm and he was diagnosed with ITP. After receiving 2 doses of oral dexamethasone his platelets improved. Synthetic cannabinoids are widely available and used psychoactive drugs. Little is known about the complete chemical composition of the synthetic products thus there is relatively little information available on the pharmacodynamic and pharmacokinetic effects. A high index of suspicion is needed to diagnose toxicity to these drugs since there are no readily available on-site lab tests. Currently there exists 1 case report of ITP induced by K2/Spice. Here, we discuss another case of K2/Spice a as a potential cause of immune thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30531235     DOI: 10.1097/ADM.0000000000000485

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  1 in total

1.  Anti-Neuronal Autoantibodies (Cell Surface and Onconeural) and Their Association With Natural Autoantibodies in Synthetic Cannabinoid-Induced Psychosis.

Authors:  Lídia Hau; Tamás Tényi; Natália László; Márton Áron Kovács; Szabina Erdö-Bonyár; Zsuzsanna Csizmadia; Tímea Berki; Diána Simon; Györgyi Csábi
Journal:  Front Psychiatry       Date:  2022-05-02       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.